James (Jay) E. Bradner, M.D. is an American Physician-Scientist and Drug Developer.

Presently, he serves as Executive Vice President for Research & Development and Chief Scientific Officer for

Amgen (Thousand Oaks, California). In this role, he leads an integrated global discovery research, early and

confirmatory clinical development organization across four therapeutic areas and two therapeutic modalities.

Additionally, he serves on the CEO Staff as an Amgen executive. A focus of Amgen R&D is the development

of definitive medicines for serious illnesses, incisively invoking human genetics to discover new targets and

creatively leveraging multi-specific platforms to short-circuit disease processes. Within and beyond Amgen, he

has contributed to the regulatory approval of 25 medicines.

Immediately before joining Amgen, Dr. Bradner enjoyed a return to clinical service as a Stem Cell Transplant

physician at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital, teaching at Harvard Business

School and MIT, and advising Blackstone Financial Group and the FNIH.

He has also served as President of the Novartis Institutes for BioMedical Research (NIBR) and as a member of

the Executive Committee of Novartis, from 2016 to 2022. In this role, he led global Research and early Drug

Development for internal and external innovation, through NIBR Business Development and the Novartis

Venture Fund. In his seven years of leadership, NIBR innovated 80 development candidates, filed 75 INDs and

reported out 90 positive proof-of-concept studies in human clinical investigation.

Earlier in his career, Dr. Bradner served on the research faculty of Harvard Medical School and as an attending

physician within the Department of Medical Oncology at the Dana-Farber Cancer Institute. The research focus

of the Bradner laboratory had been the study of BET bromodomain proteins and their function in gene control,

innovating chemical probes and investigational drugs to study and treat cancer. Further, the Bradner laboratory

pioneered an all-chemical strategy for targeted protein degradation, broadly used today in investigational

therapeutics. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 250

scientific publications and 50 United States patent applications.

Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed

residency in Medicine at Brigham & Women's Hospital, fellowship in Medical Oncology and Hematology at

the Dana-Farber Cancer Institute and postdoctoral training in Chemistry and Chemical Biology at Harvard

University (Prof. Stuart Schreiber).